Aldafermin

Phase 2Protein / enzyme

NNGM Biopharmaceuticals, Inc

Aldafermin is one of 73 small molecule programs targeting Diarrhea. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Sclerosing CholangitisActive, not recruiting

CirrhosisActive, not recruiting

Sclerosing CholangitisPhase 2/Phase 3

Active, not recruiting

CirrhosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

252 competitors in Cirrhosis

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Preclinical

2 2

Dobutrex

Eli Lilly

Preclinical

1 3

Azulfidine

Pfizer

Preclinical

1 4

HEPCLUDEX

Gilead

Preclinical

1 5

Farxiga

AstraZeneca

Preclinical

1 6

Thalomid

Bristol-Myers Squibb

Preclinical

1 7

Revia

Teva

Preclinical

1 8

Cipro

Bayer

Preclinical

1 9

Aldafermin

NNGM Biopharmaceuticals, Inc

Phase 2

1 10

Coreg

Akero Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diarrhea1 trial

Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

Completed·MMichael Camilleri, MD·Phase 2·NCT05130047·30 enrolled

Adult1 trial

Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects

Completed·NNGM Biopharmaceuticals, Inc·Phase 1·NCT04828265·36 enrolled

Sclerosing Cholangitis1 trial

A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.

Withdrawn·NNGM Biopharmaceuticals, Inc·Phase 2/3·NCT06654726

Cirrhosis1 trial

Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

Completed·NNGM Biopharmaceuticals, Inc·Phase 2·NCT04210245·160 enrolled

Hepatic Function1 trial

Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

Completed·NNGM Biopharmaceuticals, Inc·Phase 1·NCT04823702·36 enrolled

1 more indication

Impaired Renal Function1 trial

Study of Aldafermin (NGM282) in Participants With Impaired Renal Function

Completed·NNGM Biopharmaceuticals, Inc·Phase 1·NCT04179630·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Aldafermin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aldafermin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aldafermin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NGM Biopharmaceuticals, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: NNGM Biopharmaceuticals, Inc

Aldafermin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diarrhea1 trial

Adult1 trial

Sclerosing Cholangitis1 trial

Cirrhosis1 trial

Hepatic Function1 trial

Impaired Renal Function1 trial

References

Drug Info

Quick Facts

Related News